STOCK TITAN

[SCHEDULE 13G] Nektar Therapeutics SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Integrated Core Strategies (US) LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:07/02/2025
Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:07/02/2025
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:07/02/2025
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:07/02/2025

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of July 2, 2025, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

Nektar Therapeutics

NASDAQ:NKTR

NKTR Rankings

NKTR Latest News

NKTR Latest SEC Filings

NKTR Stock Data

521.68M
18.86M
0.84%
47.52%
5.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO